How Does FNAIT Differ in Asian vs. Caucasian Populations?

If your doctor mentioned that your baby’s Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is caused by a different antigen than usual, they are likely referring to how FNAIT genetics vary by ethnicity. While an HPA-1a mismatch causes 80-90% of FNAIT cases in people of Caucasian (European) descent, it is extremely rare in Asian populations because nearly 100% of individuals with Asian ancestry carry the gene for the HPA-1a antigen ^[1]. Instead, in Asian families, FNAIT is most frequently caused by an incompatibility involving the HPA-4b antigen (sometimes part of what is called the Yuk system) ^[2].

While a FNAIT diagnosis is daunting, it is helpful to know that if your case is caused by an HPA-4b mismatch, your care team already knows how to manage it. The diagnosis methods and treatment plans are the same established protocols used for the more common HPA-1a mismatch ^[3][4].

Why the Genetics Differ

FNAIT happens when a mother’s immune system does not recognize a specific marker on the surface of platelets (called a Human Platelet Antigen, or HPA) determined by genes inherited from the father, causing her body to produce antibodies against the baby’s platelets ^[1].

Because gene frequencies naturally vary across global populations, the most common “mismatch” depends on your genetic background (this can also affect mixed-ethnicity families):

• In Caucasian populations: The mother typically lacks the HPA-1a antigen, and the baby inherits it from the father.
• In Asian populations: Because almost everyone is positive for the HPA-1a antigen, this type of mismatch almost never occurs ^[1]. Instead, a mother might lack the HPA-4b antigen, while the baby inherits the gene for HPA-4b from the father ^[2].

Do Symptoms or Risks Change?

The specific antigen involved does not change the core mechanism of how FNAIT affects the baby. The maternal antibodies still cross the placenta and lower the baby’s platelet count ^[3]. The risks—including the risk of severe bleeding or intracranial hemorrhage (bleeding in the brain)—are considered highly comparable between HPA-1a and HPA-4b mismatches ^[3]. (Note: Some other, less common HPA mismatches, like HPA-5b, may carry a different risk profile, but HPA-1a and HPA-4b are both treated as high-risk and managed proactively ^[5]).

Diagnosis and Treatment Are the Same

Your care team will follow the same standard protocols used for any high-risk case of FNAIT:

• Diagnosis: Doctors will use specialized blood tests to identify the specific maternal antibody and check the genotypes (genetic makeup) of both parents ^[6]. Processing times for these tests may occasionally vary depending on the lab’s familiarity with testing for HPA-4b.
• Treatment During Pregnancy (Antenatal): To protect the baby and prevent severe bleeding complications, specialists such as Maternal-Fetal Medicine (MFM) doctors or Hematologists will use the same established treatments, most commonly weekly Intravenous Immunoglobulin (IVIG) ^[4][7].
• Treatment After Birth (Postnatal): If the newborn’s platelet count is severely low, they will receive a platelet transfusion ^[8].

A Note on Blood Donations

The only practical difference between HPA-1a and HPA-4b cases involves sourcing platelets for a transfusion. To be safe and effective, transfused platelets must be “antigen-negative” for the specific marker causing the mismatch ^[8]. This means a baby with an HPA-4b mismatch needs HPA-4b negative platelets.

Because gene frequencies vary, blood banks may sometimes need to look harder or use specialized registries to find these perfectly matched donor platelets. However, care teams are well aware of this logistical challenge. They routinely coordinate with blood banks well in advance of your delivery date to ensure the right platelets are on hand. If a perfectly matched donor cannot be found in time, hospitals have backup plans—such as using specialized treatments like IVIG or, in some cases, utilizing the mother’s own washed platelets—to safely manage the baby’s platelet levels.